Regimen Reference Order – MYEL – lenalidomide maintenance

ARIA: MYEL - [lenalidomide (maint)]

Planned Course:	Orally daily until disease progression or unacceptable toxicity	
	(1 cycle = 28 days)	
Indication for Use:	Multiple Myeloma Maintenance post autologous stem cell transplant	

Proceed with treatment if:

Day 1 of every cycle & Day 15 of Cycles 1 and 2

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $30 \times 10^9/L$

* Contact prescribing hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements						
Drug	Dose	CCMB Administration Guideline				
Not Applicable						

Drug	Dose	CCMB Administration Guideline
enalidomide	10 mg	Orally once daily with or without food
		Swallow whole
		(Self-administered at home)

REQUIRED MONITORING

Cycles 1 and 2

Day 1

- CBC, serum creatinine, electrolytes, calcium, albumin, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Day 15

• CBC as per Physician Orders

Cycle 3 and Onwards

Day 1

- CBC, serum creatinine, electrolytes, calcium, albumin, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Per RevAid Program or Reddy2Assist Program – See Additional Information

• Patients of childbearing potential require βHCG according to RevAid/Reddy2Assist Program requirements



Recommended Support Medications						
Drug	Dose	CCMB Administration Guideline				
None required						

INSTRUCTIONS FOR PATIENT

• Reinforce applicable safe handling precautions of medications, blood and body fluids while on lenalidomide

ADDITIONAL INFORMATION

- lenalidomide starts 3 to 4 months post autologous stem cell transplant
- lenalidomide is teratogenic
- Patients of childbearing potential will require monthly pregnancy tests (βHCG) that must be done within 7 days of the next prescription fill
- Effective November 25th, 2021, all new patients starting on lenalidomide will be enrolled in Reddy2Assist Program and lenalidomide will be dispensed by CCMB Pharmacy. lenalidomide can only be given to patients who are registered and meet all conditions of Reddy2Assist Program
- Existing patients on lenalidomide (started prior to November 25th, 2021) are currently enrolled in RevAid Program and will continue to have their lenalidomide prescriptions dispensed by the RevAid Registered Pharmacy

